AVIA Biosystems
Stage
Acquired | AcquiredTotal Raised
$2.35MRevenue
$0000About AVIA Biosystems
AVIA Biosystems is dedicated to developing and commercializing new products for the biochemical and biophysical characterization of biologics and other biomolecules. The first product to be developed by AVIA is the fluorescence-based Model 2304 Fully Automated Protein Denaturation System.
Missing: AVIA Biosystems's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: AVIA Biosystems's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing AVIA Biosystems
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
AVIA Biosystems is included in 1 Expert Collection, including Biopharma Tech.
Biopharma Tech
5,241 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
AVIA Biosystems Patents
AVIA Biosystems has filed 4 patents.

Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
5/12/2015 | 3/28/2017 | Monoclonal antibodies, Molecular biology, Proteins, Biotechnology, Pharmaceutical industry | Grant |
Application Date | 5/12/2015 |
---|---|
Grant Date | 3/28/2017 |
Title | |
Related Topics | Monoclonal antibodies, Molecular biology, Proteins, Biotechnology, Pharmaceutical industry |
Status | Grant |
Latest AVIA Biosystems News
Jun 4, 2015
Acquires AVIA Biosystems PLEASANTON, Calif., June 4, 2015 /PRNewswire/ -- Unchained Labs upped its game in the biologics stability market today, announcing the acquisition of AVIA Biosystems, the developer of the Isothermal Chemical Denaturation (ICD) system for measuring biologic stability. This is the second acquisition for Unchained Labs this year. The ICD system makes something that wasn't possible before — the routine measurement of protein stability under denaturing conditions — totally doable. It completely automates the complex sample prep and data analysis needed to make these measurements, giving formulation scientists a true walk-away solution. The ICD system is also a perfect complement for Unchained Labs' first product, the UNit, which simultaneously measures the top two biologic stability indicators, protein unfolding and aggregation temperatures. "We are totally committed to improving biologics characterization tools and the ICD is a great new tool that can actually help predict future drug stability," said Tim Harkness, Founder and CEO of Unchained Labs. "The ICD and the UNit are a perfect pairing and really help establish us as the experts in protein stability. We have done a lot and done it quickly at Unchained Labs, but we are unwavering in our pledge to acquire any product or business that can make a real difference for biologics researchers. " "I'm really looking forward to joining forces with the Unchained Labs team," said Dr. Rick Brown, Co-founder and President of AVIA Biosystems. "Together, our products will give drug discovery researchers the power to characterize and understand their biologics better than they ever could before. " Unchained also announced the addition of $6 million to its Series A Financing, bringing the total Series A round to $31M. The original syndicate partners, Novo Ventures, Canaan Partners and TPG Biotech all participated in the financing. About Unchained Labs Unchained Labs is committed to building the first cool biologics tools company. One that matters. One without old school rules. One with products that'll make a real difference in the research scientists do every day. We plan to buy businesses and product lines and then add our magic touch for developing breakthrough products and selling them like crazy. We are located in Pleasanton, CA and can be found online at www.unchainedlabs.com . Contact:
AVIA Biosystems Frequently Asked Questions (FAQ)
Where is AVIA Biosystems's headquarters?
AVIA Biosystems's headquarters is located at 6940 Koll Center Parkway, Pleasanton.
What is AVIA Biosystems's latest funding round?
AVIA Biosystems's latest funding round is Acquired.
How much did AVIA Biosystems raise?
AVIA Biosystems raised a total of $2.35M.
Who are the investors of AVIA Biosystems?
Investors of AVIA Biosystems include Unchained Labs and National Institutes of Health.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.